Harnessing New Potential in Generalized Myasthenia Gravis (gMG)

This session provides an in-depth review of current and emerging treatment options for generalized myasthenia gravis (gMG), emphasizing the importance of aligning therapy with individual patient needs and goals. Faculty discuss the latest evidence for conventional and novel agents—including FcRn and complement inhibitors—while highlighting real-world patient cases that illustrate the challenges of disease management, treatment selection, and balancing efficacy with tolerability. The program underscores the value of shared decision-making, patient-reported outcomes, and multidisciplinary collaboration to improve quality of life for adults living with gMG. Practical considerations such as insurance access, side effect profiles, and the need for flexible, patient-centered care are woven throughout the discussion.